Mastic gum Pistacia lentiscus L.
Also called: mastic, mastiha, Chios mastic gum, mastic tree resin
Mastic gum is the resin of the mastic tree, Pistacia lentiscus. Chios mastic gum, from Pistacia lentiscus var. Chia, is produced only in the southern part of the Greek island of Chios. The EU monograph covers the powdered resin.
- Category
- Botanical
- Part used
- Resin (powdered, for oral or skin use)
- Strongest evidence
- C Limited
- Native range
- Native to the Canary Islands and the Mediterranean (POWO: "Canary Is., Medit.")
- Reviewed
- 2026-10-29
Class 2 Moderately studied in people. No review stating a count was found; a 2023 Cochrane review found 1 trial for dyspepsia. This entry cites 3 RCTs of mastic gum alone: sources 2, 4 and 5, versus placebo, no intervention or standard H. pylori therapy. [2]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Functional dyspepsia in adults | C | A double-blind RCT in 148 patients (350 mg three times daily for 3 weeks) found lower dyspepsia symptom scores than placebo; marked improvement occurred in 77% versus 40%. [2] |
| Functional dyspepsia (Cochrane assessment) | C | A 2023 Cochrane review rated this single trial (148 participants; SMD −0.33 versus placebo) as low-certainty evidence that mastic may improve dyspepsia symptoms. [3] |
| Functional dyspepsia (crossover trial) | C | A randomized three-way crossover trial (4-week phases) reported fewer symptoms with mastiha capsules (1.4 g/day) or mastiha-water than in a no-intervention period; there was no placebo. [4] |
| Helicobacter pylori infection | C | In a pilot RCT of 52 infected patients, mastic gum alone for 14 days cleared infection in 4/13 and 5/13; standard triple therapy cleared 10/13. [5] |
| Inflammatory bowel disease | C | A 2023 systematic review found eight human and animal studies (seven from Greece; clinical doses 2.2–2.8 g/day) and concluded that more high-quality clinical trials are needed for reliable conclusions. [6] |
Main constituents: More than 120 compounds identified; the major components are a natural polymer, acidic and neutral triterpenes, and volatile secondary metabolites [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Studied in trials: 350 mg three times daily for 3 weeks (functional dyspepsia RCT). [2]
- Studied in trials: 350 mg or 1.05 g three times daily for 14 days (H. pylori pilot RCT). [5]
- Stated in a regulatory monograph (EU, EMA HMPC, 2016), traditional use in mild dyspeptic disorders, adults: powdered resin 0.5–1 g twice daily (daily dose 1–2 g). [7]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingEU monograph (2016): in the absence of sufficient data, use during pregnancy and lactation is not recommended. No fertility data available.
1 statement in the profile.
Details and sources - Interactions with medicinesNone reported
Medicines in general: EU monograph (EMA HMPC, 2016), section 4.5: none reported.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked. The profile notes other test results.
Details and sources - FDA new dietary ingredient notifications2 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographs2 statements
EU (EMA HMPC monograph, 2 February 2016), traditional use, mild dyspeptic disorders, adults and elderly: powdered resin 0.5–1 g twice daily …
Details and sources
- The EU monograph lists no known undesirable effects; hypersensitivity to mastic is a contraindication. [7]
- The EU monograph does not recommend use during pregnancy and lactation (insufficient data), and oral use under 18 years has not been established (lack of adequate data). [7]
- In the H. pylori pilot trial, all patients tolerated mastic gum well and no serious adverse events were reported. [5]
- Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed (EU monograph). [7]
Identity, quality and standardization
- The EU monograph refers to material that complies with the European Pharmacopoeia monograph for mastic (ref. 1876). [7]
Regulatory status
- US: FDA's published NDI notification list has 2 entries naming Chios mastic gum (earliest NDI 1242 submitted 2022-02-15; most recent NDI 1322 submitted 2024-01-23). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [8]
- EU: EMA's HMPC monograph (2016) recognizes traditional use of powdered mastic orally in mild dyspeptic disorders and on the skin for minor inflammations and minor wounds, based on long-standing use. [7]
- US: FDA states that under DSHEA it does not have the authority to approve dietary supplements before they are marketed, and that it generally does not approve supplement claims or other labeling before use. [9]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 2 entries naming Chios mastic gum (earliest NDI 1242 submitted 2022-02-15; most recent NDI 1322 submitted 2024-01-23). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of mastic gum was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P3]
- NTP technical reports list checked: no report on mastic or Pistacia lentiscus. [P4]
- The EU monograph states that carcinogenicity tests have not been performed. [P5]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- Medicines in general: EU monograph (EMA HMPC, 2016), section 4.5: none reported. [P5]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test of each dietary-ingredient lot (at least one appropriate test or examination) — Required for any component that is a dietary ingredient under 21 CFR 111.75(a)(1)(i), unless FDA grants a petition exemption. [P6]
- Compliance with the European Pharmacopoeia monograph for mastic (ref. 1876) — The EU herbal monograph defines the material by reference to this Ph. Eur. monograph. [P5]
Supply and conservation
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- EU (EMA HMPC monograph, 2 February 2016), traditional use, mild dyspeptic disorders, adults and elderly: powdered resin 0.5–1 g twice daily; daily dose 1–2 g; see a doctor if symptoms last more than 2 weeks. [P5]
- EU (same monograph), minor skin inflammations and minor wounds, from 12 years: semi-solid preparations with 9–11% powdered resin, thin layer up to 3 times daily. [P5]
Pregnancy and breastfeeding
- EU monograph (2016): in the absence of sufficient data, use during pregnancy and lactation is not recommended. No fertility data available. [P5]
Sources for this profile
- Pachi VK, et al. Traditional uses, phytochemistry and pharmacology of Chios mastic gum (Pistacia lentiscus var. Chia, Anacardiaceae): a review. J Ethnopharmacol 2020;254:112485 (PMID 32092498), 2020-05-23. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. Agents Classified by the IARC Monographs, Volumes 1–142 (list last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (list of 2-year studies; checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- European Medicines Agency (HMPC). European Union herbal monograph on Pistacia lentiscus L., resina (mastic). EMA/HMPC/46758/2015 (2 February 2016), 2016-02-02. ema.europa.eu
- eCFR. 21 CFR 111.75 What must you do to determine whether specifications are met? (text retrieved through the eCFR versioner API, version of 2026-09-01), 2026-09-01. ecfr.gov
- GBIF species API: IUCN Red List category for Pistacia lentiscus, 2026-10-29. api.gbif.org
Sources
- Pachi VK, et al. Traditional uses, phytochemistry and pharmacology of Chios mastic gum (Pistacia lentiscus var. Chia, Anacardiaceae): a review. J Ethnopharmacol 2020;254:112485 (PMID 32092498), 2020-05-23. pubmed.ncbi.nlm.nih.gov
- Dabos KJ, et al. Is Chios mastic gum effective in the treatment of functional dyspepsia? A prospective randomised double-blind placebo controlled trial. J Ethnopharmacol 2010;127(2):205-9 (PMID 19961914), 2010-02-03. pubmed.ncbi.nlm.nih.gov
- Báez G, et al. Non-Chinese herbal medicines for functional dyspepsia. Cochrane Database Syst Rev 2023;6:CD013323 (PMID 37323050), 2023-06-15. pubmed.ncbi.nlm.nih.gov
- Kleftaki SA, et al. A randomized, three-way crossover clinical trial on the efficacy of Mastiha based therapies (Pistacia lentiscus var. Chia) in functional dyspepsia. Pharmacol Res 2025;222:108019 (PMID 41197785), 2025-12. pubmed.ncbi.nlm.nih.gov
- Dabos KJ, et al. The effect of mastic gum on Helicobacter pylori: a randomized pilot study. Phytomedicine 2010;17(3-4):296-9 (PMID 19879118), 2010-03. pubmed.ncbi.nlm.nih.gov
- Mavroudi A, et al. The effect of Mastic Chios supplementation in inflammatory bowel disease: a systematic literature review. J Med Food 2023;26(4):215-223 (PMID 37001176), 2023-04. pubmed.ncbi.nlm.nih.gov
- European Medicines Agency (HMPC). European Union herbal monograph on Pistacia lentiscus L., resina (mastic). EMA/HMPC/46758/2015 (2 February 2016), 2016-02-02. ema.europa.eu
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Pistacia lentiscus L. (accessed 2026-10-29). powo.science.kew.org
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.